Involving A Micro-organism Or Cell Membrane Bound Antigen Or Cell Membrane Bound Receptor Or Cell Membrane Bound Antibody Or Microbial Lysate Patents (Class 435/7.2)
  • Patent number: 11066630
    Abstract: The present invention provides an integrated microphysiological device and fabrication methods thereof, as well as methods of use to perform biological assays.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: July 20, 2021
    Assignee: The Johns Hopkins University
    Inventors: Onur Kilic, Steven An, Andre Levchenko
  • Patent number: 11067581
    Abstract: The invention encompasses methods and test strips for detecting the presence of cerebrospinal fluid (CSF) in a biological sample comprising removing sialo-transferrin and selectively detecting or measuring asialo-transferrin in the biological sample.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 20, 2021
    Assignees: NSPC TECHNOLOGIES, LLC, RENSSELAER POLYTECHNIC INSTITUTE
    Inventors: Seok-Joon Kwon, Robert J. Linhardt, Jonathan S. Dordick, William J. Sonstein, Fuming Zhang
  • Patent number: 10980853
    Abstract: The present invention provides a process for the preparation of a Crassocephalum crepidioides extract, and the extract prepared thereby. The present invention further relates to a pharmaceutical composition/combination comprising the Crassocephalum crepidioides extract. The use of the extract and the composition/combination comprising the extract in the prevention or treatment of cancer is also provided.
    Type: Grant
    Filed: December 31, 2015
    Date of Patent: April 20, 2021
    Assignee: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Dai-Hua Tsai, Tzung Hsien Lai, Tsui Hsu Chan, Yuh Shan Chung, Li-Chuan Hsu
  • Patent number: 10981167
    Abstract: Embodiments disclosed herein are directed to microfluidic devices that allow for scalable on-chip screening of combinatorial libraries and methods of use thereof. Droplets comprising individual molecular species to be screened are loaded onto the microfluidic device. The droplets are labeled by methods known in the art, including but not limited to barcoding, such that the molecular species in each droplet can be uniquely identified. The device randomly sorts the droplets into individual microwells of an array of microwells designed to hold a certain number of individual droplets in order to derive combinations of the various molecular species. The paired droplets are then merged in parallel to form merged droplets in each microwell, thereby avoiding issues associated with single stream merging. Each microwell is then scanned, e.g., using microscopy, such as high content imaging microscopy, to detect the optical labels, thereby identifying the combination of molecular species in each microwell.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 20, 2021
    Assignees: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Paul Blainey, Anthony Kulesa, Jared Kehe
  • Patent number: 10982263
    Abstract: A method for analyzing planar sample is provided. In some cases the method comprises: (a) labelling the planar sample with a capture agent that is linked to a nucleic acid, wherein the capture agent specifically binds to complementary sites in the planar sample; (b) reading a fluorescent signal caused by extension of a primer that is hybridized to the nucleic acid, using fluorescence microscopy. Several implementations of the method, and multiplexed versions of the same, are also provided.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: April 20, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Nikolay Samusik, Garry P. Nolan, Yury Goltsev, David Robert McIlwain
  • Patent number: 10973679
    Abstract: A condom for detection of STDs, including an interior condom surface having a control band and a test band, and an exterior condom surface that also has a control band and test band. Each test band allows binding and subsequent detection of STD antigens. A separate developing antibody produces a color change if bound to the antigen/antibody conjugate. The developing antibody may be present on the condom or applied separately after use.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: April 13, 2021
    Inventors: Adam Arreola, Cameron R. Pye
  • Patent number: 10946042
    Abstract: The present invention relates to compositions and methods that provide novel therapies in cancer. The invention includes a phagocytic cell modified with a repressor of signal regulatory protein-alpha (SIRP?) and bound to a targeting antibody to enhance phagocytic activity of the phagocytic cell toward tumor tissue. Methods of enhancing phagocytic activity and treating a tumor are also included.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: March 16, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Dennis E. Discher, Kyle R. Spinler, Cory Alvey
  • Patent number: 10925919
    Abstract: Provided is a material effective for improving the activity of nerves in the brain or for preventing or ameliorating brain dysfunction. An agent for activating astrocyte glucose metabolism, brain nerve cells activating agent, a brain hypofunction suppressing agent, a brain function improving agent, or an agent for preventing or ameliorating brain dysfunction comprising, as an active ingredient, one or more selected from the group consisting of hydrophobic solvent extracts of tien-cha, rooibos, grape and black tea.
    Type: Grant
    Filed: January 4, 2017
    Date of Patent: February 23, 2021
    Assignee: Kao Corporation
    Inventors: Keiko Ishida, Koichi Misawa, Kohjiro Hashizume
  • Patent number: 10925962
    Abstract: Provided are: a polymeric IgA-type recombinant antibody; a medicine containing this polymeric IgA-type recombinant antibody as an active ingredient; a method for producing this polymeric IgA type antibody, the method including the step of coexpressing an IgA-type antibody heavy-chain protein, an antibody light-chain protein, an antibody J-chain protein, and a secretory component protein within a single cell; and a method for improving the antigen-binding activity or neutralizing activity of this antibody, the method including the step of making an antibody into a polymeric IgA-type.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: February 23, 2021
    Assignee: Nippi, Incorporated
    Inventors: Shinji Saito, Tadaki Suzuki, Hideki Hasegawa, Akira Ainai, Kiyoko Goto, Tomonori Ueno, Yuki Taga
  • Patent number: 10921322
    Abstract: Provided are methods of detecting a marker for active tuberculosis, and a portable device for carrying out a method of detecting a marker for active tuberculosis. Also provided is a system for carrying out a method of detecting a marker for active tuberculosis, a method for pre-treating a sample stream from a human or animal suspected of having active tuberculosis, a system for pre-treating a sample stream from a human or animal suspected of having active tuberculosis and kits for performing said methods.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: February 16, 2021
    Assignees: KEI INTERNATIONAL LIMITED, TOMORROWS IP LIMITED
    Inventor: Johannes Theodorus Castrop
  • Patent number: 10919974
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 16, 2021
    Assignees: Ganymed Pharmaceuticals GmbH, Johannes Gutenberg-Universitat Mainz
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Woll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Patent number: 10889865
    Abstract: The invention relates to methods and kits for detecting thyroid cancer by detecting differences in the expression of genes that are differentially expressed in thyroid cancer cells.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: January 12, 2021
    Assignee: Cornell University
    Inventors: Thomas J. Fahey, III, Nimmi Kapoor, Theresa Scognamiglio
  • Patent number: 10836996
    Abstract: To provide a cell culture kit including cultured living cells of various donors, and a manufacturing method thereof. The cell culture kit includes a culture plate and living cells cultured thereon. The culture plate includes a plurality of microchambers (33) and living cells derived from various donors are adhered to surfaces of the plurality of microchambers (33). Specifically, living cells D1, D2, and D3 derived from various donors are adhered to the plurality of microchambers (33). In each microchamber (33), living cells derived from one donor or living cells derived from various donors may be cultured. The living cells derived from various donors are adhered and cultured in the cell culture kit as a whole, which makes it possible to provide a cell culture kit to conduct a test using cells derived from various donors.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: November 17, 2020
    Assignees: Corning Incorporated, Public University Corporation Yokohama City University
    Inventors: Yoko Itchoda, Go Tazaki, Motohiro Fukuda, Hitoshi Tsuruta, Hideki Taniguchi
  • Patent number: 10816549
    Abstract: A method of detecting epithelial cancer is described that includes the steps of: (a) determining the level of beta defensin 3 (BD-3) and beta defensin 2 (BD-2) in a suspect sample obtained from a subject; (b) comparing the level of BD-3 to BD-2 determined in the suspect sample to obtain a suspect BD-3/BD-2 ratio, (c) comparing the suspect BD-3/BD-2 ratio to a healthy BD-3/BD-2 ratio to obtain a diagnostic BD-3/BD-2 ratio; and (d) characterizing the subject as having epithelial cancer if the diagnostic BD-3/BD-2 ratio is greater than 1. A microfluidic device for detecting epithelial cancer using the diagnostic BD-3/BD-2 ratio is also described.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: October 27, 2020
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Aaron Weinberg, Santosh Ghosh, Umut A. Gurkan
  • Patent number: 10793518
    Abstract: The present disclosure is directed dye compounds containing a hydrazinyl substituent and optionally, one or more negatively charged groups, such as sulfonate, phosphate, phosphonate, and/or carboxylate groups and dye compounds containing an aminooxy substitutent. The compounds are useful in the detection of analytes containing aldehyde and ketone groups, including, for example, glycans.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: October 6, 2020
    Assignee: Life Technologies Corporation
    Inventors: Wenjun Zhou, Kyle Gee, Yolanda Tennico, Peter Slade, Hee Chol Kang, Shaheer Khan, Brian Evans, James Stray
  • Patent number: 10780271
    Abstract: Technology for the transition of light and sound over long distances, e.g. TV and radio, has revolutionized society. On the contrary, the technology to perceive a smell remotely is in its infancy, and has severe limitations such as latency, residual and infidelity. A system and methods are disclosed to allow smells to be perceived remotely. It is based on the brain waves associated with the olfactory bulb.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 22, 2020
    Inventors: Lucas Mingzhi Zhou, Lin Zhou, Christopher Li
  • Patent number: 10768184
    Abstract: The present invention relates to a method of identifying a compound that binds to or modulates the activity of one or more polypeptides encoding one or more receptors that are involved in the detection and perception of fatty acids.
    Type: Grant
    Filed: August 8, 2019
    Date of Patent: September 8, 2020
    Assignee: MARS, INCORPORATED
    Inventors: Scott Joseph McGrane, Andrew John Taylor, Matthew Ronald Gibbs, Richard Masten Fine, Boris Klebansky
  • Patent number: 10745728
    Abstract: This invention relates to the use of analogs of purines that have two tautomeric forms, one formally complementary to thymidine, the other formally complementary to cytidine, and analogs of pyrimidines that have two tautomeric forms, one formally complementary to guanosine, the other formally complementary to adenosine. These uses include the polymerase chain reaction amplification of targets having polymorphisms in primer binding sites and ligation.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: August 18, 2020
    Inventors: Steven A Benner, Hyo-Joong Kim, Zunyi Yang
  • Patent number: 10739354
    Abstract: In one aspect, the invention relates to a method for identifying a compound which modulates the activity of a voltage-gated protein. In certain embodiments, the voltage gate protein is a voltage-gated ion channel. In certain embodiments, the voltage-gated protein is a voltage sensitive phosphatase. In certain embodiments, the voltage-gated protein used in conjunction with the methods of the invention is modified to altered permeability or voltage sensitivity.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: August 11, 2020
    Assignee: D.E. SHAW RESEARCH, LLC
    Inventors: Morten Østergaard Jensen, David Wayne Borhani, Vishwanath Jogini
  • Patent number: 10740655
    Abstract: A system and method automatically predicts an evolution of a cognitive score for a subject by classifying a cognitive data set for the subject into a first or second class by determining the cognitive set of data for each subject of a group, acquiring for each subject a neuropsychological score used for classifying each subject in the first or second class, and training a two-class machine learning classification algorithm on the cognitive data sets of all subjects. For each subject, the cognitive data set is used as input of the algorithm and the obtained classification of the subject as output target of the algorithm. The algorithm classifies each cognitive data set in the first or second class. The evolution of the cognitive score of a subject is predicted by the trained algorithm for automatically classifying a new cognitive dataset for the subject into the first or second class.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: August 11, 2020
    Assignees: Centre Hospitalier Universitaire Vaudois, Siemens Healthcare GmbH
    Inventors: Jonas Richiardi, Tobias Kober, Julius Popp
  • Patent number: 10736906
    Abstract: The present invention provides for compositions and methods for modulating tissue growth using tissue growth modulators, which are agents that either enhance or inhibit tissue growth as desired by a particular indication by modulating the PG or Wnt signaling pathways, or employing modulators of both PG and Wnt signaling pathways for a synergistic effect or highly selective effect.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: August 11, 2020
    Assignees: CHILDREN'S MEDICAL CENTER CORPORATION, THE GENERAL HOSPITAL CORPORATION
    Inventors: Leonard I. Zon, Trista E. North, Wolfram Goessling
  • Patent number: 10722509
    Abstract: Methods are provided herein for identifying whether a cancer patient, for example a colorectal cancer patient, will be responsive to treatment with a therapeutic strategy comprising administration of the FOLFOX regimen (5-fluorouracil, leucovorin, and oxaliplatin). Specified TYMP and UCK2 fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells, for example colorectal cancer tumor cells, that are collected from tumor tissue obtained from a cancer patient and compared to reference levels in order to determine if the cancer patients will positively respond to treatment with the combination treatment of FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin).
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: July 28, 2020
    Assignee: NantOmics, LLC
    Inventors: Fabiola Cecchi, Todd Hembrough
  • Patent number: 10724039
    Abstract: The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: July 28, 2020
    Assignees: Posco, Postech Academy-Industry Foundation
    Inventors: Sung Ho Ryu, Na-Oh Yunn, Jong Hun Im, Ara Koh, Eun Ju Oh, Sehoon Park, Jiyoun Lee, Sung Key Jang, Seungmin Han, Youndong Kim
  • Patent number: 10705100
    Abstract: Methods for accurately comparing the levels of ionizable lipids in two cell populations that differ in some respect from each other using mass spectroscopy and isotopic labeling are provided. The methods can be used to identify a change in a lipid of interest in response to a cellular, chemical, genetic, or environmental change to the cell population (i.e., a lipid response to a cell perturbation). The change in the lipid of interest can be a change in composition, rate of synthesis, and/or location of the lipid.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: July 7, 2020
    Inventors: Scott B. Hansen, Andrew S. Hansen
  • Patent number: 10688127
    Abstract: Methods for use of structures based on graphene-related materials are disclosed. These structures can be utilized for manipulating the cell transmembrane potential in various biomedical applications.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: June 23, 2020
    Inventor: Elena Molokanova
  • Patent number: 10639371
    Abstract: The present invention provides a bioconjugate. The bioconjugate comprises a first molecule comprising an elastin-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule. The bioconjugate is self-assembled into particles, which are disassembled when the temperature is increased. Also provided is a method for delivering a bioconjugate to a target matrix, comprising (a) introducing a bioconjugate self-assembled into particles to a target matrix, wherein the bioconjugate comprises a first molecule comprising an elastin-like peptide (ELP), a second molecule capable of self-associating into an oligomer, and a linker connecting the first molecule with the second molecule, and (b) increasing the temperature of the target matrix to disassemble the particles at the target matrix.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: May 5, 2020
    Assignee: University of Delaware
    Inventors: Kristi Kiick, Tianzhi Luo
  • Patent number: 10632175
    Abstract: The present invention is related to methods and compositions effective in regulating glycemic control in subject individuals in need of the regulation of glycemic control. Said individuals may have diabetes or be prediabetic condition receive therapeutically effective amounts of identified secreted proteins in an amount suitable for modulating glycemic control and to thereby treat or prevent diabetes in said subject.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: April 28, 2020
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Laurie J. Goodyear, Kristin I. Stanford
  • Patent number: 10627408
    Abstract: Antibodies are used as biomarkers to assist in distinguishing gluten immune reactivity and sensitivity, silent celiac disease, Crohn's disease and other gut-related pathologies from classical celiac disease. In one class of embodiments, sera, saliva or other samples from a human or other animal are tested for antibodies to (a) a wheat antigen; (b) a gliadin antigen; and (c) one or more of a wheat germ agglutinin, a gluteomorphin, a glutenin, a deamidated glutenin, a prodynorphin, and a dynorphin. Test results are considered particularly interesting where the wheat antigen and the gliadin antigen are both selected from the group consisting of native and deamidated forms of ?-gliadin 33-mer, ?-gliadin-17-mer, ?-gliadin-15-mer, ?-gliadin-17-mer, and glutenin 21-mer.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: April 21, 2020
    Assignee: Cyrex Laboratories, LLC
    Inventor: Aristo Vojdani
  • Patent number: 10611834
    Abstract: The present invention provides a screening method for a pain suppressor, which method comprises using FLRT3 to select a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord. In addition, the present invention provides a pharmaceutical composition for prevention or treatment of pain, which pharmaceutical composition comprises, as an active ingredient, a substance capable of inhibiting FLRT3 expression or a substance capable of inhibiting FLRT3 transport to the spinal cord.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: April 7, 2020
    Assignee: Osaka University
    Inventors: Toshihide Yamashita, Yasufumi Hayano, Moe Yamada
  • Patent number: 10613083
    Abstract: A biosensor system for the detection of target analytes that includes a living biological cell of a predetermined type; a signal-generating reporter associated with the living biological cell; a signal transduction pathway or other activator mechanism or means associated with the signal-generating reporter; a universal detector element associated with the activator mechanism; and an analyte binding element associated with the universal detector element, wherein the analyte binding element is specific to both the universal detector element and a target analyte.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: April 7, 2020
    Assignee: Fundamental Solutions Corporation
    Inventors: Thomas J. Zupancic, Joseph D. Kittle, Lingchun Zeng, Srikanth Vedamoorthy, Richard S. Brody, Marvin R. Williams
  • Patent number: 10597697
    Abstract: The invention discloses a method for determining a nucleotide sequence of a nucleic acid segment present in a biological sample, comprising the steps of: a) generating a fluorescent image of the sample by a protocol comprising immunofluorescence detection of at least five different target proteins in the sample; b) selecting a region of interest of the sample by comparing the image to a predetermined criterion; c) removing a subsample from the region of interest, and; d) determining a nucleotide sequence of a nucleic acid segment present in the subsample.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: March 24, 2020
    Assignee: GE Healthcare Bio-Sciences Corp.
    Inventors: John Richard Nelson, Qingyan Au, Wei Gao, Ryan Charles Heller, Nicholas Hoe, Nam Tran, Nichole Lea Wood
  • Patent number: 10591364
    Abstract: The present invention relates to the use of one or more amplicons as temperature calibrators. In some embodiments, the calibrators may be used to calibrate the temperature of a microfluidic channel in which amplification and/or melt analysis is performed. In some embodiments, the amplicons may be genomic, ultra conserved elements and/or synthetic. The amplicon(s) may have a known or expected melt temperature(s). The calibrators may be added to primers of study or may follow or lead the primers of study in the channel. The amplicon(s) may be amplified and melted, and the temperature(s) at which the amplicon(s) melted may be determined. The measured temperature(s) may be compared to the known temperature(s) at which the amplicon(s) was expected to melt. The difference(s) between the measured and expected temperatures may be used to calibrate/adjust one or more temperature control elements used to control and/or detect the temperature of the channel.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: March 17, 2020
    Assignee: Canon U.S.A., Inc.
    Inventors: Fernando DeCastro, Renee Howell, Sami Kanderian, Johnathan S. Coursey, Kenton C. Hasson, Scott Sundberg
  • Patent number: 10544472
    Abstract: A protein reporter system comprising at least one reporter including a response element responsive to the binding of a transcription factor, a secreted enzyme backbone and a recognition region for specific binding of an antibody. Multiplexed assays for binding, assaying and quantifying the activity of transcription factors are also described, in which the assays use protein reporters in sets, libraries or other groupings, as necessary to achieve desired quantification.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 28, 2020
    Assignee: ATTAGENE, INC.
    Inventors: Sergei S. Makarov, Ming Zheng
  • Patent number: 10543243
    Abstract: The invention relates to a soybean seed extract, method for producing the same and uses of the extract of soybean seeds in promoting wound healing, promoting neuron cell proliferation and/or treating brain diseases and/or neurodegenerative diseases, treating breast cancer, reducing side effects of interfering with DNA and/or RNA replication drugs and/or enhancing pharmaceutical effects of interfering with DNA and/or RNA replication drugs.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: January 28, 2020
    Assignee: CHARSIRE BIOTECHNOLOGY CORP.
    Inventor: Chu I-Hung
  • Patent number: 10539540
    Abstract: A minimum peak is determined from analysis results, a correction wavelength at which an S/N ratio of the minimum peak is greatest is determined, and the determined correction wavelength is used to execute correction of the minimum peak. A plurality of detector output value correction method are registered in a processor, correction method is selected from default correction method or from among a plurality of preset correction methods according to an object to perform correction.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: January 21, 2020
    Assignee: HITACHI HIGH-TECH SCIENCE CORPORATION
    Inventors: Shuhei Yamamura, Daisuke Akieda, Ayumi Nakaogami, Katsutoshi Shimizu
  • Patent number: 10539570
    Abstract: In various implementations, a noninvasive, food sensitivity test may be utilized to identify one or more food sensitivities. A fecal sample may be obtained. The food sensitivity test may be performed on the obtained fecal sample. One or more food sensitivities may be identified based on the food sensitivity test.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: January 21, 2020
    Inventor: Kenneth Davin Fine
  • Patent number: 10526412
    Abstract: An antibody or a fragment thereof directed against an epitope including or being constituted by at least six contiguous amino acids in the SEQ ID NO: 1 or a conformational epitope comprising or being constituted by at least six amino acids of SEQ ID NO: 1 which are always in the order of the sequence, and its use for the prognosis and/or the diagnosis of a cancer.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: January 7, 2020
    Assignees: UNIVERSITE GRENOBLE ALPES, UNIVERSITE DE LAUSANNE
    Inventors: Bertrand Huard, Pascal Schneider
  • Patent number: 10501531
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 10492717
    Abstract: A method includes receiving multiple compound muscle action potential values (CMAPs), wherein each CMAP is an onset latency, a peak latency, a conduction velocity, or a response amplitude measured from a baseline; for each of the CMAPs and for each of a number parameters calculated from the CMAPs, determining a corresponding demyelinating boundary value using a normal value from a preselected population; determining whether each of the CMAPs and each of the parameters exceeds the corresponding demyelinating boundary value; determining one or more demyelinated nerve pathways based on which of the CMAPs and the parameters exceeds the corresponding demyelinating boundary value; indicating on a display which of the CMAPs and the parameters exceed the corresponding demyelinating boundary value; and displaying, in pictorial form, an anatomical diagram indicating the demyelinated nerve pathways.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: December 3, 2019
    Assignee: The Research Foundation of State University of New York
    Inventors: Paul Jacob Maccabee, Lawrence Philip Eberle
  • Patent number: 10487114
    Abstract: The present invention features methods and compositions for the generation of conformation-specific antibodies.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: November 26, 2019
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou
  • Patent number: 10465164
    Abstract: The method provides a hyaluronic-acid binding based technique to separate functionally competent and mature sperm. The method for extracting viable sperms from a semen sample comprises incubating functionalized HA with functionalized paramagnetic beads to obtain a plurality of HA coated paramagnetic beads. The method further comprises incubating the plurality of HA coated paramagnetic beads with the semen sample to obtain a first population and a second population of sperm. The first population comprises sperm bound to the plurality of HA coated paramagnetic beads and the second population comprises sperms not bound to the plurality of HA coated paramagnetic beads. The method comprises magnetically separating the first population from the second population and separating sperms from the plurality of HA coated paramagnetic beads in the separated first population to obtain the viable sperms.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: November 5, 2019
    Assignees: ACHIRA LABS PVT. LTD., VASAN SATYA SRINI
    Inventors: Dhananjay Dendukuri, Satish Kalme, Vijetha Nagendra Prakash, Gokul R Prasath, Vasan Satya Srini
  • Patent number: 10449206
    Abstract: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: October 22, 2019
    Assignee: Natreon, Inc.
    Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
  • Patent number: 10416162
    Abstract: In certain aspects, the present invention provides methods for determining whether a Her-2 positive cancer is likely to respond to treatment with a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a slow disease progression. In other aspects, the present invention is drawn to methods for determining whether a subject with a Her-2 positive cancer is unlikely to respond to treatment with at least one chemotherapeutic agent in addition to a Her2-acting agent and/or whether a patient with a Her-2 positive cancer is likely to have a fast disease progression.
    Type: Grant
    Filed: December 19, 2008
    Date of Patent: September 17, 2019
    Assignee: Monogram Biosciences, Inc.
    Inventors: Weidong Huang, Jeff Sperinde, Michael Bates, Colombe Chappey, John William Winslow
  • Patent number: 10371696
    Abstract: The invention provides a multiparametric method of assessing the reaction of a patient's immune system to a test subject. The invention compares a patient sample reacted with a test sample and a third party sample and combines the assessments of the multiple parameters to correlate the test reaction with a clinical event.
    Type: Grant
    Filed: August 16, 2017
    Date of Patent: August 6, 2019
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventor: Rakesh Sindhi
  • Patent number: 10365283
    Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: July 30, 2019
    Assignee: Daiichi Sankyo Europe GmbH
    Inventors: Mike Rothe, Martin Treder
  • Patent number: 10351823
    Abstract: Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 16, 2019
    Assignee: Q THERAPEUTICS, INC.
    Inventors: Robert Sandrock, James T. Campanelli, Deborah A. Eppstein
  • Patent number: 10336806
    Abstract: The present invention discloses cryopreserved recombinant cells for screening drug candidates that transiently overexpress one or more drug transporter proteins and/or drug metabolizing enzymes. Advantageously, such cells provide a cost-efficient consumable product that streamlines the process of screening whether drug candidates are substrates or inhibitors of drug transporter proteins and/or drug metabolizing enzymes.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 2, 2019
    Assignee: Corning Incorporated
    Inventors: Na Li, Jie Wang, Christopher J. Patten
  • Patent number: 10324098
    Abstract: Newly identified mammalian taste-cell-specific G Protein-Coupled Receptors and the genes encoding said receptors are described. Specifically, T2R taste G Protein-Coupled Receptors that are believed to be involved in bitter taste sensation, and the genes encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating a novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: June 18, 2019
    Assignee: SENOMYX, INC.
    Inventor: Jon Elliot Adler
  • Patent number: 10214584
    Abstract: The present invention aims to provide a pharmaceutical composition for cancer treatment, which comprises a novel monoclonal antibody binding to SLC6A6 or its extracellular region and a chemotherapeutic agent conjugated therewith, as well as a therapeutic method in which the monoclonal antibody or a therapeutic agent composed of the monoclonal antibody conjugated with a chemotherapeutic agent is used in combination with a chemotherapeutic agent. The present invention provides a pharmaceutical composition comprising an antibody conjugate configured such that a monoclonal antibody having higher affinity than conventional antibodies and recognizing native SLC6A6 or a native polypeptide of an extracellular region of SLC6A6 is conjugated with an anticancer agent or the like having activity against cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: February 26, 2019
    Assignee: ORDER-MADE MEDICAL RESEARCH INC.
    Inventors: Hiroyuki Satofuka, Kensuke Ohse, Shigeki Mukobata, Hirotada Akiyama, Masaya Ohtsu, Yoko Okabe, Yasufumi Murakami
  • Patent number: 10160978
    Abstract: The invention relates to mammalian cells comprising at least one prokaryotic two-component signaling (TCS) pathway comprised of an activator protein A, a response regulator (RR) protein B activated by said protein A, such activation leading to an activated RR protein B, and an output gene C operably linked to a promoter. Transcription from said promoter is activated by activated RR protein B, and the expression of output gene C defines at least a first state (0, no transcription) and a second state (1, detectable transcription). The invention further relates to logic gates designed from such cells, and methods for integrating a plurality of output signals based on the cells and logic gates of the invention.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: December 25, 2018
    Assignee: ETH ZURICH
    Inventors: Yaakov Benenson, Jonathan Hansen, Krishna Kumar Swaminathan